Medtronic plc. ($MDT) Stock Forecast: Up 5.0% Today

What is Medtronic plc.?

Medtronic (NYSE: MDT) saw a significant increase in its stock price today driven by robust Q4 earnings that outperformed analyst projections. The stock surged by 4.30% due to favorable market sentiment and analyst upgrades.

Why is Medtronic plc. going up?

MDT stock is up 5.0% on Jun 4, 2026 19:56

• Medtronic's impressive Q4 earnings, reporting adjusted earnings of $1.55 per share and revenue of $9.81 billion, surpassed analyst estimates, instilling greater confidence among investors and leading to a bullish trend in the stock price.
• Analysts at BTIG upgraded Medtronic from Neutral to Buy, while Leerink Partners maintained an Outperform rating, recognizing the company's sustained organic growth and appealing valuation relative to industry peers. These actions further fueled investor confidence.
• The disclosure that Medtronic is seeking FDA approval to expand the applications of its Hugo surgical robot to include general and gynecological procedures showcases the company's strategic initiatives to broaden its market presence and enhance competitiveness against players like Intuitive Surgical. This development has contributed to the positive market sentiment and upward movement in Medtronic's stock price.

MDT Price Chart

MDT Technical Analysis

MDT News

Wall Street May Be Mispricing Medtronic, Analyst Says

Medtronic (NYSE: MDT) reported strong Q4 earnings, exceeding analyst expectations with adjusted earnings of $1.55 per share and revenue of $9.81 billion. BTIG upgraded Medtronic from Neutral to Buy, citing consistent organic growth and the stock trading at a discount compared to peers, while Leerink Partners maintained an Outperform rating despite lowering its price forecast, seeing an attractive setup for the stock. Medtronic shares rose 4.30% following the news.

https://www.benzinga.com/analyst-stock-ratings/upgrades/26/06/53014062/wall-street-may-be-mispricing-medtronic-analyst-says

Is Intuitive Surgical (ISRG) Fairly Priced After A 27% One Year Share Price Decline?

Intuitive Surgical (ISRG) has seen a 27% share price decline over the last year, prompting a valuation analysis. A Discounted Cash Flow (DCF) model indicates the stock is currently fairly valued at around $407 per share, aligning closely with its intrinsic value estimate. However, its Price-to-Earnings (P/E) ratio of 48.42x suggests it is overvalued compared to the Medical Equipment industry average and Simply Wall St's Fair Ratio of 31.27x.

https://simplywall.st/stocks/us/healthcare/nasdaq-isrg/intuitive-surgical/news/is-intuitive-surgical-isrg-fairly-priced-after-a-27-one-year

Medtronic seeks clearance for Hugo surgical robot in more indications

Medtronic has filed for 510(k) clearance from the FDA to expand the use of its Hugo surgical robot into general and gynecological procedures. This move aims to broaden Hugo's market reach beyond urological procedures, enabling Medtronic to better compete with Intuitive Surgical's da Vinci robots in major robotic surgery markets. The company noted that Hugo has already contributed to an 8% growth in its U.S. medical surgical sales in the fourth quarter.

https://www.medtechdive.com/news/medtronic-seeks-clearance-for-hugo-surgical-robot-in-more-indications/821969/

Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com

Canaccord Genuity has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a buy rating and a price target of $32.00, citing the company's differentiated cardiac ablation platform. Pulse Biosciences uses nanosecond pulsed field ablation, an evolution of existing technology, which Canaccord believes could lead to significant commercial adoption. Despite the positive outlook, analysts do not expect the company to be profitable this year, though recent Q1 2026 results showed an EPS beat and insider stock purchases indicate strong confidence.

https://m.in.investing.com/news/stock-market-news/canaccord-initiates-pulse-biosciences-stock-with-buy-on-ablation-tech-93CH-5440569?ampMode=1

Jim Cramer on GE HealthCare: “Maybe It’s Too Expensive”

Jim Cramer discussed GE HealthCare (GEHC), noting its modest 3-4% organic growth and 13 times earnings valuation, suggesting it might be too expensive. He advised a caller to sell GEHC stock, preferring other medical device companies like Medtronic or Abbott, as he believes GEHC does not have the same upside as GE Vernova and GE Aerospace. The article also suggests that certain AI stocks may offer better investment opportunities than GE HealthCare.

https://sg.finance.yahoo.com/news/jim-cramer-ge-healthcare-maybe-105832618.html

Trending Today

Medtronic plc. Price History

04.01.2026 - MDT Stock was down 2.8%

• The retirement announcement of Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has led to uncertainty among investors regarding future leadership and strategic direction in that segment, resulting in a bearish movement in the stock.
• Despite Medtronic's acquisition plans for CathWorks and the positive news of institutional investors increasing their stakes in the company, the market reaction may be linked to concerns about the potential impact of leadership changes on key product lines.
• The projected growth potential in the continuous glucose monitoring devices market, with a estimated market size of US$10.72 billion by 2033, might be overshadowed by worries about the immediate leadership transition within Medtronic's structural heart division.
• The current bearish movement in Medtronic's stock may stem from a combination of profit-taking following recent positive developments and investor caution regarding upcoming changes in crucial leadership positions within the company.

05.00.2026 - MDT Stock was up 0.7%

• Medtronic PLC (MDT) experienced a strong bullish movement today.
• The company exceeded Q3 earnings estimates, reporting $1.36 EPS and $8.96 billion in revenue, and provided a positive forecast for FY26 EPS.
• The market movement could be attributed to a firm lowering its stake in MDT by 9.9% in Q3, potentially signaling confidence in the company's future performance.
• The overall positive sentiment towards AI-powered medical stocks, including MDT, as highlighted in discussions focusing on the integration of AI in the medical sector, could have also contributed to the bullish movement.

04.05.2026 - MDT Stock was up 5.1%

• Medtronic's stock price target was lowered to $101 from $120 due to peer multiple contraction, despite the company's strong financial performance.
• Jim Cramer recommended preferring Medtronic over GE HealthCare and Danaher, highlighting its potential for growth.
• The market movement could be influenced by investors' focus on Medtronic's undervaluation and strong product cycle growth.
• Despite the peer multiple contraction, Medtronic's stock is trading near its 52-week low, indicating a potential buying opportunity for investors.

04.05.2026 - MDT Stock was up 5.1%

• Medtronic's bullish movement today is linked to the decision to expand the use of its Hugo surgical robot into general and gynecological procedures, expected to boost competitiveness.
• The comparison of Medtronic with Intuitive Surgical (ISRG) by Jim Cramer could have influenced investor sentiment positively, favoring Medtronic in valuation and growth potential.
• Positive sentiment towards medical device companies in general and Medtronic specifically, as highlighted by Jim Cramer, likely supported the stock's upward movement.
• Investor confidence in Medtronic's strategic expansion of Hugo's applications reflects optimism about the company's positioning in the robotic surgery market and growth prospects.

04.05.2026 - MDT Stock was up 5.0%

• Medtronic's impressive Q4 earnings, reporting adjusted earnings of $1.55 per share and revenue of $9.81 billion, surpassed analyst estimates, instilling greater confidence among investors and leading to a bullish trend in the stock price.
• Analysts at BTIG upgraded Medtronic from Neutral to Buy, while Leerink Partners maintained an Outperform rating, recognizing the company's sustained organic growth and appealing valuation relative to industry peers. These actions further fueled investor confidence.
• The disclosure that Medtronic is seeking FDA approval to expand the applications of its Hugo surgical robot to include general and gynecological procedures showcases the company's strategic initiatives to broaden its market presence and enhance competitiveness against players like Intuitive Surgical. This development has contributed to the positive market sentiment and upward movement in Medtronic's stock price.

18.10.2025 - MDT Stock was up 5.1%

• Following its Q2 earnings, Medtronic (MDT) saw a strong upward trend in its stock value, buoyed by exceeding earnings expectations and showcasing robust growth in the Cardiovascular segment.
• The company's revised 2026 outlook also bolstered investors' confidence, leading to a rise in the stock price.
• Analysts' positive forecast adjustments prior to the earnings announcement foreshadowed a strong performance, paving the way for the stock's climb post-earnings.
• Market response indicates investor trust in Medtronic's financial stability and growth opportunities, driving the stock's ascent as optimism for future success grows.

18.10.2025 - MDT Stock was up 6.0%

• Medtronic (MDT) surpassed earnings and revenue forecasts for the second quarter, demonstrating strong financial results.
• Analysts raised their projections before the earnings announcement, indicating confidence in the company's expansion opportunities.
• The optimistic projections for Medtronic's Cardiovascular unit and Diabetes segment potentially influenced the stock's upward movement, highlighting potential growth in these key sectors.
• Overall, investors reacted favorably to Medtronic's robust performance and promising future prospects, leading the stock to climb higher.

03.05.2026 - MDT Stock was up 6.0%

• The submission of 510(k) filings to expand the Hugo™ robotic-assisted surgery system and the clearance for ProGrip™ Advanced mesh demonstrate Medtronic's dedication to enhancing its product portfolio and reaching new markets.
• The Q4 2026 financial results showed a mix of performance, surpassing revenue expectations with significant growth in the Cardiovascular segment, which enhanced investor confidence in Medtronic's present and future prospects.
• Despite a slight initial stock decrease due to earnings guidance slightly below consensus for fiscal year 2027, the overall optimism regarding Medtronic's investments in cardiac ablation technologies and robust revenue growth in fiscal 2026 likely drove the positive movement witnessed today.

03.05.2026 - MDT Stock was up 5.4%

• Medtronic (MDT) stock demonstrated a bullish trend today, potentially influenced by several factors:
• Strong Q4 2026 earnings performance surpassing revenue expectations, highlighting the company's robust financial position and growth potential.
• Submission of 510(k) filings for expanding the Hugo™ robotic-assisted surgery system into new specialties, signaling a focus on innovation and market growth.
• Mizuho's reduced price target, coupled with a maintained Outperform rating, might have been seen as an opportunity by investors, particularly in light of Medtronic being deemed undervalued by InvestingPro.
• Discussions on earning $500 per month from Medtronic stock dividends could have enticed investors seeking income, potentially contributing to the bullish movement.

03.05.2026 - MDT Stock was up 5.1%

• Medtronic's positive movement today is a result of its impressive Q4 2026 earnings, exceeding revenue projections and achieving the highest annual revenue growth in ten years.
• The company's expansion of the Hugo™ robotic-assisted surgery system into new specialties through 510(k) filings highlights its dedication to innovation and widening market presence.
• Investors seeking stable returns in a volatile market have likely been attracted by Medtronic's consistent dividend payments, boasting a 3.83% yield.
• Medtronic's focus on enriching its product offerings, strategic acquisitions, and robust financial performance have collectively fostered favorable market sentiment and the upward trajectory of its stock.